Lixte Biotechnology to acquire NOMAD Transportable Power Systems, pivoting to energy storage

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

Consideration: up to 50,500 Series D Convertible Preferred shares ($1,000/sh, convertible at $1.00) plus up to 3M common shares.
Closing condition: Lixte must hold at least $16.5M unrestricted cash; proxies for 33% of common stock to approve conversion.
NOMAD revenue grew ~175% YoY in 2025, projected ~135% YoY growth in 2026; ~75% of sales inbound and >30 active opportunities.
Company to be renamed NOMAD Power Solutions; John Travaglini named CEO of merger sub and board member.
NOMAD first-to-market with mobile, utility-grade 1 MW BESS; UL 9540 validated, bypassing permanent BESS permitting delays.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.